EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clearside Biomedical's Enterprise Value is $-5.70 Mil.
Clearside Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was $-21.75 Mil. Therefore, Clearside Biomedical's EV-to-FCF for today is 0.26.
The historical rank and industry rank for Clearside Biomedical's EV-to-FCF or its related term are showing as below:
CLSDQ'
s EV-to-FCF Range Over the Past 10 Years
Min: -81.93 Med: -2.78 Max: 393.82
Current: 0.26
During the past 12 years, the highest EV-to-FCF of Clearside Biomedical was 393.82. The lowest was -81.93. And the median was -2.78.
CLSDQ's EV-to-FCF is ranked better than 89.7% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs CLSDQ: 0.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clearside Biomedical's PE Ratio (TTM) for today is calculated as:
Clearside Biomedical's share price for today is $0.125.
Clearside Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clearside Biomedical EV-to-FCF Related Terms
Clearside Biomedical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clearside Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's EV-to-FCF falls into.
Clearside Biomedical's current Enterprise Value is $-5.70 Mil.
Clearside Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a EV-to-FCF of 0.26 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #34 out of 330 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Clearside Biomedical's EV-to-FCF too high?
Clearside Biomedical's current EV-to-FCF is 0.26. The Biotechnology industry median EV-to-FCF is 16.30. Clearside Biomedical's value of 0.26 is 98.4% below this industry median. Based on the distribution chart, Clearside Biomedical ranks #34 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's EV-to-FCF compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #34 out of 330 companies for EV-to-FCF. This places Clearside Biomedical in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.30. Clearside Biomedical's value of 0.26 is 98.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearside Biomedical's current EV-to-FCF of 0.26 is 98.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clearside Biomedical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current EV-to-FCF is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current EV-to-FCF is 0.26 and 98.4% below the Biotechnology industry median of 16.30. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current EV-to-FCF is 0.26 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
EV-to-FCF: 0.26
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
Industry Position: 98.4% below the Biotechnology median (#34 of 330)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
